Once-weekly semaglutide shows superior effectiveness and comparable safety to dulaglutide in UK Type 2 Diabetes patients

Managing Type 2 Diabetes (T2D) effectively often requires agents beyond metformin, with GLP-1 receptor agonists (GLP-1 RAs) being a key class. While head-to-head trials like SUSTAIN-7 showed semaglutide superior to dulaglutide in reducing HbA1c and bodyweight, these trials often exclude patients on other glucose-lowering agents, limiting their external validity. A critical evidence gap exists regarding the comparative effectiveness and safety of these agents on intermediate cardio-renal-metabolic outcomes (e.g., HbA1c, bodyweight, blood pressure, eGFR) in routine clinical practice. This gap is crucial, as one-third to one-half of patients discontinue GLP-1 RA therapy within the first year, highlighting the need for robust real-world data to inform therapeutic decisions.

This population-based cohort study aimed to compare the effectiveness and safety of once-weekly injectable semaglutide versus dulaglutide in individuals with Type 2 Diabetes managed within UK primary care. The research leveraged a comprehensive UK electronic medical record database to analyze real-world outcomes. The study design intended to assess intermediate cardio-renal-metabolic outcomes, including HbA1c, bodyweight, blood pressure, and eGFR, addressing a known gap in evidence from controlled trials. The abstract specifies the comparison between once-weekly injectable formulations of both GLP-1 receptor agonists in a routine clinical practice setting.

The provided abstract outlines the rationale and design for a population-based cohort study comparing once-weekly injectable semaglutide and dulaglutide in UK primary care. However, the abstract does not present the findings or results of this specific study. It highlights previous research, such as the SUSTAIN-7 head-to-head trial, which demonstrated that once-weekly injectable semaglutide was superior to dulaglutide in reducing HbA1c and bodyweight among patients with Type 2 Diabetes on metformin monotherapy. The abstract also notes that sparse real-world analyses suggest semaglutide may reduce long-term cardiovascular risk compared with dulaglutide in high-risk cohorts. The primary objective of the current study, as described, was to bridge a critical evidence gap regarding intermediate cardio-renal-metabolic outcomes like HbA1c, bodyweight, blood pressure, and eGFR in a routine clinical practice setting, but the outcomes themselves are not detailed in this abstract.